BPC-157 and TB-500 are the two most-studied research peptides in the tissue-repair space, and are often discussed together — but they act through entirely different mechanisms. Neither is FDA-approved, and the human evidence base for both is limited.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Origin | Stable fragment of body-protection compound (gastric) | Synthetic fragment of thymosin β4 |
| Chain length | 15 AA (pentadecapeptide) | 7 AA actin-binding motif (LKKTETQ) |
| Primary mechanism | Angiogenesis (VEGFR2) + cytoprotection | G-actin sequestration → cell migration |
| Signaling | Nitric-oxide & growth-factor modulation | Actin dynamics, downstream migration/angiogenesis |
| Most-studied for | Tendon/ligament & GI-tract repair | Cell migration, soft-tissue & cardiac repair (preclinical) |
| Evidence base | Largely rodent models; scant human data | Largely rodent models; scant human data |
| FDA approval | None | None |
| WADA status | Prohibited (S0/S2 context) | Prohibited (S2) |
Because the two act on non-overlapping pathways — BPC-157 on angiogenesis and cytoprotection, TB-500 on actin-driven cell migration — repair-focused research protocols sometimes examine them in combination on the rationale that they address different stages of the repair cascade. This is a mechanistic rationale, not a proven clinical synergy: rigorous human combination data does not exist.
Both should be read as preclinical research compounds. The bulk of published evidence is from animal models, and neither has completed controlled human trials for any repair indication.
These are complementary research tools, not interchangeable ones: BPC-157’s evidence centers on angiogenesis and GI/tendon cytoprotection, TB-500’s on actin regulation and cell migration. For both, the strongest data is preclinical, and human efficacy/safety for repair endpoints remains unestablished. Treat any comparison as a mechanistic contrast, not a clinical recommendation.
BPC-157 is a 15-amino-acid stable gastric peptide studied for angiogenesis (via VEGFR2) and cytoprotection, with a research focus on tendon, ligament, and GI repair. TB-500 is a synthetic fragment of thymosin β4 that sequesters G-actin and is studied for cell migration and cytoskeletal regulation. They act through different mechanisms.
They are sometimes studied in combination because they target different parts of the repair process — BPC-157 on angiogenesis/cytoprotection and TB-500 on actin-driven cell migration. This is a mechanistic rationale; controlled human data on the combination does not exist. This page is a research reference, not a protocol.
Neither is FDA-approved for any indication. Both are research compounds, and both are prohibited in sport by the World Anti-Doping Agency. Most published evidence for either is from animal models.
TB-500 is a synthetic peptide based on thymosin β4 — typically representing the actin-binding region (the LKKTETQ motif) rather than the full 43-residue protein. Research framing should distinguish the marketed fragment from native thymosin β4.